TY - JOUR
AU - Carvalho, Kevin
AU - Faivre, Emilie
AU - Pietrowski, Marie J
AU - Marques, Xavier
AU - Gomez-Murcia, Victoria
AU - Deleau, Aude
AU - Huin, Vincent
AU - Hansen, Jan N
AU - Kozlov, Stanislav
AU - Danis, Clément
AU - Temido-Ferreira, Mariana
AU - Coelho, Joana E
AU - Mériaux, Céline
AU - Eddarkaoui, Sabiha
AU - Gras, Stéphanie Le
AU - Dumoulin, Mélanie
AU - Cellai, Lucrezia
AU - Landrieu, Isabelle
AU - Chern, Yijuang
AU - Hamdane, Malika
AU - Buée, Luc
AU - Boutillier, Anne-Laurence
AU - Levi, Sabine
AU - Halle, Annett
AU - Lopes, Luisa V
AU - Blum, David
TI - Exacerbation of C1q dysregulation, synaptic loss and memory deficits in tau pathology linked to neuronal adenosine A2A receptor.
JO - Brain
VL - 142
IS - 11
SN - 0006-8950
CY - Oxford
PB - Oxford Univ. Press
M1 - DZNE-2020-00342
SP - 3636-3654
PY - 2019
AB - Accumulating data support the role of tau pathology in cognitive decline in ageing and Alzheimer's disease, but underlying mechanisms remain ill-defined. Interestingly, ageing and Alzheimer's disease have been associated with an abnormal upregulation of adenosine A2A receptor (A2AR), a fine tuner of synaptic plasticity. However, the link between A2AR signalling and tau pathology has remained largely unexplored. In the present study, we report for the first time a significant upregulation of A2AR in patients suffering from frontotemporal lobar degeneration with the MAPT P301L mutation. To model these alterations, we induced neuronal A2AR upregulation in a tauopathy mouse model (THY-Tau22) using a new conditional strain allowing forebrain overexpression of the receptor. We found that neuronal A2AR upregulation increases tau hyperphosphorylation, potentiating the onset of tau-induced memory deficits. This detrimental effect was linked to a singular microglial signature as revealed by RNA sequencing analysis. In particular, we found that A2AR overexpression in THY-Tau22 mice led to the hippocampal upregulation of C1q complement protein-also observed in patients with frontotemporal lobar degeneration-and correlated with the loss of glutamatergic synapses, likely underlying the observed memory deficits. These data reveal a key impact of overactive neuronal A2AR in the onset of synaptic loss in tauopathies, paving the way for new therapeutic approaches.
KW - Animals
KW - Autopsy
KW - Complement C1q: metabolism
KW - Frontotemporal Lobar Degeneration: genetics
KW - Frontotemporal Lobar Degeneration: metabolism
KW - Hippocampus: metabolism
KW - Hippocampus: pathology
KW - Humans
KW - Memory Disorders: etiology
KW - Memory Disorders: psychology
KW - Mice
KW - Mice, Transgenic
KW - Mutation
KW - Neurons: metabolism
KW - Receptor, Adenosine A2A: genetics
KW - Receptor, Adenosine A2A: metabolism
KW - Spatial Learning
KW - Synapses: pathology
KW - Tauopathies: genetics
KW - Tauopathies: pathology
KW - Tauopathies: psychology
KW - tau Proteins: genetics
KW - ADORA2A protein, human (NLM Chemicals)
KW - Adora2a protein, mouse (NLM Chemicals)
KW - MAPT protein, human (NLM Chemicals)
KW - Receptor, Adenosine A2A (NLM Chemicals)
KW - tau Proteins (NLM Chemicals)
KW - Complement C1q (NLM Chemicals)
LB - PUB:(DE-HGF)16
C6 - pmid:31599329
C2 - pmc:PMC6821333
DO - DOI:10.1093/brain/awz288
UR - https://pub.dzne.de/record/144978
ER -